Abstract Background: Increased prevalence of antinuclear antibodies (ANA) and auto glutamic acid decarboxylase antibodies (GADA) ratio have been reported in patients with epilepsy. Anti-GAD antibodies (GADA) were first implicated in the pathogenesis of some neurological diseases including epilepsy. The aim of the study: To determine the occurrence of GADA and ANA in the serum of children with refractory epilepsy. Patients and methods: Forty children with refractory epilepsy 25 males and 15 females, mean age 9.17 ± 3.4 years were selected for this study. Patients with refractory epilepsy had recurrent seizures for more than 18 months with no more than a 3-month seizure free period during those 18 months and failure of at least two appropriate AEDs with proper doses, good compliance and within normal therapeutic range. Twenty children with controlled idiopathic epilepsy 15 males and 5 females newly diagnosed as suffering from various types of seizures generalized and partial types, mean age 10.1 ± 3.1 years were also included in this study. These children with idiopathic epilepsy were included in this study for comparison with children with refractory epilepsy as regard to the serum ANA and GADA. Results: Children with refractory epilepsy had high-serum levels of GADA and ANA in comparison to children with idiopathic epilepsy (P < 0.001), also there was a significant correlation between the duration of seizures and the serum levels of ANA and GADA in children with refractory epilepsy.
Conclusion: Children with refractory epilepsy had high-titer of GADA and ANA. The finding confirmed the association between high GADA, ANA and refractory epilepsy suggesting an immunologic origin of refractory epilepsy.
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Introduction
Epilepsy represents the most common serious neurological problem-affecting children, with an overall incidence approaching 2% for febrile seizures and 1% for idiopathic epilepsy. 1, 2 At present, the epilepsy of childhood is most frequently classified using variations of the International Classification of Epileptic Seizures. 3 This nomenclature delineates seizures in three general categories: generalized, partial (focal), and special epileptic syndromes. 4 Epilepsy is a benign condition in the majority of cases, and 60-70% of patients who are diagnosed with epilepsy will eventually enter remission when adequately treated with antiepileptic drugs (AEDs). 5 In 40-60% of these seizure free individuals, AEDs can be successfully withdrawn after a reasonable period of time. 6 About one third of patients with newly diagnosed epilepsy do not achieve seizure control despite medical therapy and should be assessed in detail to confirm the diagnosis, to determine the epilepsy syndrome and to plan treatment strategy. 7 Refractory epilepsy is established when there is inadequate seizure control despite using potentially effective antiepileptic drugs (AEDs) at tolerable levels for 2 years, and excluding non epileptic events and poor compliance. 8 Some authors define intractable epilepsy as failure of two appropriate AEDs, the occurrence of an average of one seizure per month for P18 months, and no more than a 3-month seizure free period during those 18 months. 9 Risk factors for refractoriness include (1) generalized epilepsy with lesions; (2) focal epilepsy with hippocampus sclerosis, cortical dysplasia or hemorrhages; (3) early epilepsy onset; (4) high seizure frequency; (5) absence of response to the first 2 AEDs; (6) high frequency of inter ictal spikes; (7) multifocal spikes. A younger age at onset of epilepsy predicts refractoriness. 10 The concept that the immune system plays a role in the epileptogenic process of some epileptic syndromes was first proposed more than 20 years ago. 11 Since then numerous studies have reported on the existence of a variety of immunological alterations in epileptic patients, on the observation of favorable responses of refractory epilepsy syndromes to immunomodulatory treatment. 12 Over the last few years, antibodies to intracellular proteins such as glutamic acid decarboxylase (GAD) and antinuclear antibodies (ANA) have been detected in the serum and cerebrospinal fluid of patients with certain forms of epilepsy. 13 The increased prevalence of autoantibodies is more strongly associated with epilepsy, perhaps indicating that immune dysregulation may be commonly associated with epilepsy.
14 Previous studies have shown the association between antinuclear antibodies and epilepsy but there are no studies addressing the effect of seizure frequency, duration of epilepsy, epilepsy type and etiology on the prevalence of these antibodies in well-evaluated refractory epilepsy. 15 Glutamic acid decarboxylase (GAD) catalyzes the transformation of glutamate into c-hydroxybutyric acid (GABA), both are major neurotransmitters of the central nervous system. 16 GAD primarily is expressed in GABA-secreting neurons and in pancreatic b cells, which also may secrete GABA as a paracrine signal molecule. 17 Glutamic acid decarboxylase antibodies (GADA) have been detected in patients with epilepsy; some patients with drug-resistant localization-related epilepsy have evidence of GAD autoimmunity. 18 The presence of autoantibodies to brain endothelial cells suggests that autoimmunity may be important in the pathogenesis of epilepsy. 19 The aim of the study
We studied the frequency of antinuclear antibodies (ANA) and autoantibodies to glutamic acid decarboxylase (GADA) in the serum of children with refractory epilepsy and compared them with children with controlled idiopathic epilepsy to delineate if immune mechanisms might be participating in the mechanism of refractory epilepsy and to determine whether autoantibodies were associated with some subtypes of epilepsy.
Patients and methods
The present study was carried out in Tanta University Hospital, Pediatric Department, Neurology unit, during a 12-month period from January 2011 to January 2012. Forty children with refractory epilepsy 25 males and 15 females, age range 4-15 years with the mean age of 9.17 ± 3.4 years were selected for this study. Patients with refractory epilepsy had recurrent seizures for more than 18 months with no more than a 3-month seizure free period during those 18 months and failure of at least two appropriate AEDs with proper doses, good compliance and within normal therapeutic range, Table 1 . Thorough history of the age of onset, detailed medical history, types of seizures, frequency, duration, history of the AEDs given including the dose and the compliance and duration as well as family history of similar conditions, obstetric history of any complication during delivery and past history of trauma were obtained from the parents. Electroencephalography (EEG) and Magnetic Resonance Imaging (MRI) brain, and the serum level of the AEDs were done for the epileptic children. Exclusion criteria included, false refractoriness related to non-epileptic seizures, inadequate AEDs, poor combination of AEDs, sub therapeutic range of AEDs, non-compliance and seizure-precipitating factors. Also children with chronic inflammatory diseases, diabetes mellitus, liver or renal impairment, cardiac and pulmonary diseases were excluded from the study. Twenty (20) children with controlled idiopathic epilepsy 15 males and 5 females newly diagnosed as suffering from various types of seizures generalized and partial types were included, 16 of them had generalized seizures and 4 children had partial seizures, aged 4-13 years with the mean age being 10.1 ± 3.1 years. These children were free of any neurological diseases and had normal brain Magnetic Resonance Imaging (MRI). They were free of any systemic diseases by clinical and neurological examination, they had two or more unprovoked seizures and abnormal Electroencephalography (EEG) and diagnosed as idiopathic epilepsy, these children are seizure free six months ago. These children with idiopathic epilepsy were included in this study for comparison with children with refractory epilepsy as regard to the serum ANA and GADA.
Complete blood count including cell count for the major immune cell populations i.e., neutrophils, lymphocytes, eosinophils, monocytes and platelets was done. Other routine laboratory tests, including liver function, kidney function and fasting blood sugar were done for all children. Serum antinuclear antibodies (ANA) and autoantibodies to glutamic acid decarboxylase (GADA) were measured for all children. All children participated in the study after written informed parental consent was obtained. The local ethics committee of the Faculty of Medicine Tanta University approves the study. Venous blood samples were collected in the morning after an overnight fast. The fasting blood samples were allowed to clot for 30 min then centrifuged and the serum obtained was collected into clean dry tubes and stored at À20°C till the time of the assay for detection of auto antibodies to glutamic acid decarboxylase (GADA) and antinuclear antibodies(ANA).
Determination of human anti-glutamic acid decarboxylase (Anti-GAD) by ELIZA kit supplied by Uscn Life Science INC. Cat. No. E3245Hu
Principle of the assay
The micro titer plate provided in this kit has been pre-coated with antigen. Standards and samples were then added to the appropriate micro titer plate wells with a biotin-conjugated antigen. Next, Avidin conjugated to Horseradish Peroxidase (HRP) was added to each micro plate well and incubated. Then a TMB substrate solution was added to each well. Only those wells that contain Anti-GAD, biotin-conjugated antigen and enzyme conjugated Avidin exhibited a change in color. The enzyme-substrate reaction was terminated by the addition of a sulfuric acid solution and the color change was measured spectrophotometrically at a wavelength of 450 nm. The concentration of Anti-GAD in the samples was then determined by comparing the O.D. of the samples to the standard curve. 20 Determination of antinuclear antibody (ANA) by ELIZA kit supplied by bioassay Cat. No. A2298-12J
Principle of the assay Anti-nuclear antibodies (ANA) ELISA kit was based on binding of ANA from standard and serum samples to extracted nuclear antigen (ENA) immobilized on micro titer wells. After a washing step, goat anti-mouse HRP conjugate was added. After another washing step, to remove all the unbound enzyme conjugate, chromogenic substrate (TMB) was added and color developed. The enzymatic reaction (blue color) was directly proportional to the amount of ANA present in the sample. The reaction was terminated by adding stopping solution (converts blue to yellow). Absorbance was then measured on a micro titer well ELISA reader at 450 nm. 21 
Statistical analysis
Collected data were coded, analyzed and computed using the Statistical Package for Social Sciences (SPSS) version 10. Results are expressed as mean ± SD, and differences between the means of different variables tested using the Student's ttest. Differences were considered statistically significant when P < 0.05. Pearson correlation was done to correlate the duration of refractory epilepsy and the serum ANA and GAD antibodies. Table 1 shows the characteristics of children with refractory epilepsy with regard to the age of the children, currently used AEDs, duration of treatment, age of the first seizure in years and the EEG finding in these children. Table 2 shows the types of seizures in children with refractory epilepsy, 55% of them had partial seizures, 15% had generalized tonic clonic seizures, 10% had myoclonic seizures, 15% had atonic seizures and 5% had mixed type of seizures. Table 3 shows the frequency of seizures in children with refractory epilepsy, 70% of them had the frequency of Ponce/month, 25% of them had the frequency of Ponce/week, 5% of them had the frequency of once/day. Table 4 shows the types of AEDs used, 15% of children with refractory epilepsy treated with valproic acid + carbamazepine, 30% of these children treated with valproic acid + levetiracetam, 20% of them treated with carbamazepine + lamotrigine, 15% treated with valproic acid + topiramate, 10% treated with valproic acid + levetiracetam + carbamazepine, another 10% treated with valproic acid + topiramate + clonazepam. Table 5 shows the serum ANA levels in children with refractory epilepsy and children with controlled epilepsy; serum ANA was significantly higher in children with refractory epilepsy than the serum level of ANA in children with controlled epilepsy P < 0.001. Table 6 shows the serum GAD antibodies in children with refractory epilepsy and children with controlled epilepsy. Serum GAD antibody levels were significantly higher in children with refractory than in children with controlled epilepsy P < 0.001. Fig. 1 shows a correlation between the serum levels of ANA and the duration of refractory epilepsy.
Results
There was a significant correlation between the duration of refractory epilepsy and the serum ANA, r: 0.975, P < 0.001. Fig. 2 shows a correlation between the serum levels of GAD antibodies and the duration of refractory epilepsy. There was a significant correlation between the duration of refractory epilepsy and the serum GAD antibodies r: 0.99, P < 0.001. Increased duration of refractory epilepsy was associated with increased serum levels of ANA and GADA.
Discussion
In a substantial number of patients with epilepsy, the etiology of the seizure disorder remains unknown. 22 In recent years, the detection of autoantibodies has contributed to the etiologic understanding of a substantial number of unexplained epilepsies. 23 The concept that the immune system plays a role in the epileptogenic process of some epileptic syndromes was first proposed more than 20 years ago. 24 This study assessed the prevalence of ANA and GADA in children with refractory and controlled epilepsies. Increased prevalence of ANA and GADA has been reported in patients with refractory epilepsy. 25 It is highly possible that the production of antineuronal antibodies might be initiated by prolonged seizures leading to blood-brain barrier leakage, it is still remarkable to observe a relatively increased incidence of anti-neuronal antibodies in a group of patients with long-term epilepsy, since these antibodies might still at least partially be participating in epilepsy pathogenesis and somewhat increasing the seizure severity and frequency. 26 High GADA and ANA titers were present in patients with refractory epilepsy suggesting that the most probable origin of their epilepsy is autoimmune and an active ongoing immunologic process in the brain. 27 GADA seem to play an essential role in neuronal dysfunction and seizure susceptibility. 28 Sera from GADA-positive patients with epilepsy caused a significant increase in the frequency of inhibitory postsynaptic potentials in hippocampal neurons, supporting that GAD autoimmunity is involved in the pathophysiology of neuronal dysfunction. 29 The synthesis of the inhibitory neurotransmitter GABA was decreased in knockout mice lacking GAD, leading to spontaneous seizures supporting the importance of GAD in neuronal excitability. 30 A relationship between epilepsy and GADA and ANA suggesting a possible role of such antibodies in the pathophysiology of epilepsy, antiglutamic acid decarboxylase (anti-GAD) antibodies in the serum and cerebrospinal fluid (CSF) has been reported in patients with drug-resistant epilepsy, some patients with drug-resistant epilepsy have evidence of GAD autoimmunity. 31 The results of the present study had shown that, children with refractory epilepsy had increased serum levels of ANA and GAD antibodies in comparison to children with controlled epilepsy. These results agree with the result obtained by Peltola et al., 32 who had reported that, patients with refractory epilepsy had higher serum levels of GADA than the controls. Also the results of the present study agree with the results obtained by Falip et al., 33 who had found elevated serum levels of GAD antibodies and ANA in adult patients with temporal lobe epilepsy. On the other hand, the results of the present study are contradictory to the results obtained by Kwan et al., 34 who had found no significant difference in the absolute titer of GAD autoantibody between adult patients with controlled and uncontrolled epilepsy. Glutamic acid decarboxylase (GAD) catalyzes the transformation of glutamate into c-hydroxybutyric acid (GABA), both are major inhibitory neurotransmitters of the central nervous system. 35 The pathophysiological importance of GADA in our patients is not clear but low levels of GABA in the brain and CSF are associated with uncontrolled epilepsy, indicating that GABA is crucial in seizure suppression. 36 In conclusion, we identified a subgroup of epileptic patients with high-serum ANA and GADA. The finding confirmed the association between high GADA and refractory epilepsy. 37 All the patients with high-titer GADA in the serum suggesting an immunologic origin of their epilepsy and high GADA and ANA might indicate an active ongoing immunologic process in the brain. 13 Based on our findings, a study on the effectiveness of immunosuppressive therapy in patients with refractory epilepsy with high GADA titer is suggested. Further studies for patients with epilepsy are needed to clarify the significance of GADA in the etiology of epilepsy because these antibodies themselves may be directly implicated in causing epilepsy.
Conclusion
We identified children with refractory epilepsy who had hightiter of GADA and ANA. This finding confirmed the association between high GADA and refractory epilepsy, suggesting an immunologic origin of refractory epilepsy. The measurement of these antibodies may be useful in evaluating the outcome of epilepsy. Immunosuppressive drugs may lead to improvement in children with refractory epilepsy. Further studies are needed to clarify the significance of GADA in the etiology of refractory epilepsy. Anti GADA should be actively sought out in pharmacoresistant epilepsy.
